- 期刊
- OpenAccess
Comparing the Effects between Atorvastatin 40 mg and Ezetimibe/Simvastatin 10/20 mg on Lipoprotein Parameters and Inflammatory Markers among Patients with Type 2 Diabetes Mellitus and Hyperlipidemia
摘要
Background. Diabetic dyslipidemia has a complex nature and is composed of a cluster of atherogenic lipoproteins. Statin is the foundation in the management of diabetic dyslipidemia. Methods. The study is a 12-week, randomized, open labeled study in subjects with type 2 diabetes mellitus and hyperlipidemia. Our study aimed to evaluate lipid and inflammation modification effects between two lipid-lowering drugs, atorvastatin 40 mg and vytorin 10/20 mg (10mg ezetimibe combined with 20 mg simvastatin) in patients with type 2 diabetes and dyslipidemia. Results. After three months of treatment, both atorvastatin 40 mg and vytorin 10/20 mg treatments could significantly lower total cholesterol, low-density lipoprotein cholesterol, triglycerides, and oxidized low-density lipoprotein as compared with the baseline. However, there were no significant differences in changes of lipid parameters and inflammatory markers between the two treatments. Conclusion. The present study shows comparable short-term effects of atorvastatin 40 mg and vytorin 10/20 mg treatments on selected lipid parameters and inflammatory markers in type 2 diabetes patients with hyperlipidemia.
延伸閱讀
- 胡啟民, 郭清輝, 陳涵栩, 石光中, 李聖葒, 蕭麗娟, 林淑霞, & 何橈通 (2000). Lack of Effect of Simvastatin on Insulin Sensitivity in Type 2 Diabetic Patients with Hypercholesterolaemia: Results from a Double-Blind, Randomized, Placebo-Controlled Crossover Study. 中華民國內分泌暨糖尿病學會會訊, 14(1), 31-32. https://www.airitilibrary.com/Article/Detail?DocID=a0000018-200010-14-1-31-32-a
- Liu, S. C. (2012). Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea [master's thesis, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU.2012.02541
- Meguro, S., Tomita, M., Katsuki, T., Kato, K., Oh, H., Ainai, A., Ito, R., Kawai, T., Itoh, H., & Hasegawa, H. (2014). Plasma Antimicrobial Peptide LL-37 Level Is Inversely Associated with HDL Cholesterol Level in Patients with Type 2 Diabetes Mellitus. International Journal of Endocrinology, 2014(), 575-580-160. https://doi.org/10.1155/2014/703696
- Chen, Y. J., Hsieh, M. C., Yang, C. C., & Hwu, C. M. (2018). Hypoglycemia-Related Emergency Department Visits in Patients with Type 2 Diabetes Mellitus: Focusing on DPP-IV inhibitor vs. Sulfonylurea Treatment on Top of Metformin. Formosan Journal of Endocrinology and Metabolism, 9(1), 10-17. https://doi.org/10.6856/FJEM.201806_9(1).0002
- Abbas, A., Milles, J., & Ramachandran, S. (2012). Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia. Clinical Medicine Insights: Endocrinology and Diabetes, (2012), 13-30. https://doi.org/10.4137/CMED.S7591